secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-05-21T23:59:59+00:00
Accession:  0000950170-24-062656
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for SAB Biotherapeutics' T1D therapy SAB-142 Phase 1 trial
-------------------------------------------------------------------------

- FDA cleared IND for SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes.
- Phase 1 HUMAN trial is randomized, double-blind, placebo-controlled, single-ascending dose (0.03-2.5 mg/kg).
- Enrollment of US patients with type 1 diabetes now permitted; third cohort dosed with no serum sickness.
- Topline results from the MELD-ATG study expected in 2025.
- SAB-142 aims to delay onset or progression of stage 3 type 1 diabetes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024062656/0000950170-24-062656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024062656/sabs-20240521.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-062656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer